Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COMAL

Financiado

Cerrado

COMAL COhesin Mutations in Acute Leukemia from modeling and mechanisms to novel...

COMAL COhesin Mutations in Acute Leukemia from modeling and mechanisms to novel therapeutics Transcriptional dyregulation is a common driver in cancer and acute myeloid leukemia (AML) is an exemplar of this process. AML has a dismal survival rate of <30% with novel targeted therapies urgently required. My research focuses... ver más

28/02/2021

THE CHANCELLOR MAS...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-28

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

THE CHANCELLOR MASTERS AND S...

2.00M€ | Lider

BODEGAS RIOJANAS

230.05K€ | Participante

Proyectos interesantes

PID2020-117950RA-I00

Medical Technol...

Data Science

218K€ Cerrado

NovLeuReg

Medical Technol...

Data Science

212K€ Cerrado

PID2020-114638RA-I00

Medical Technol...

Data Science

229K€ Cerrado

AML-SynergyX

Medical Technol...

Data Science

186K€ Cerrado

ChromatinTargets

Medical Technol...

Data Science

1M€ Cerrado

BERG

Medical Technol...

Data Science

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 66 meses Fecha Inicio: 2015-08-03
Fecha Fin: 2021-02-28

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Transcriptional dyregulation is a common driver in cancer and acute myeloid leukemia (AML) is an exemplar of this process. AML has a dismal survival rate of <30% with novel targeted therapies urgently required. My research focuses on improving our understanding of the biology of AML and using this knowledge to develop targeted therapies to improve outcomes. Recently loss-of-function mutations in members of the cohesin complex have been described in up to 15% of patients with AML. The cohesin complex mediates sister chromatid cohesion, an important process for DNA repair and proper chromosomal segregation. It has also recently been demonstrated to be important for transcriptional regulation, due to its coordination of communication between promoters and enhancer and insulator elements. Evidence suggests that transcriptional alterations underlie the mechanisms of transformation by cohesin mutations in AML. However, other evidence and my preliminary data also suggest cohesin mutant cells to have specific vulnerabilities related to their roles in proper chromosome segregation and DNA repair that can be specifically targeted. Objectives: 1) Generation of mouse models of cohesin-mutated AML. To model AML in vivo and as a resources for Obj 2-4 2) Characterisation of transcriptional defects in cohesin-mutated AML using state-of-the-art genomic techniques (RNA-Seq, ChIP-Seq and Capture Hi-C) 3) Define mechanisms of cohesin-mediated transcriptional regulation in normal hematopoiesis and its alteration in leukaemia using SILAC based proteomics and ChIP-Seq co-binding 4) Therapeutic targeting of the cohesin complex in cohesin-mutant AML using compounds identified in a large screen and suggested by Obj 1-3 and tested in cell lines, patient samples and in vivo models. This proposal will inform mechanisms of transcriptional regulation that occur during normal hematopoiesis and how these are altered in AML. It will also identify candidate therapies for this aggressive disease

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores